ADME Toxicology Testing Market To Reach $11.44 Billion By 2030

ADME Toxicology Testing Market Growth & Trends

The global ADME toxicology testing market size is expected to reach USD 11.44 billion by 2030, expanding at a CAGR of 10.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors such as increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is used to test toxic reactions caused by molecules in clinical trials on factors and systemic reactions such as chemical, pharmaceutical, and genetic. These toxicology testing procedures help in effective drug development, which limits or prevents toxic reactions to the body when administered. Toxicity levels are decided on the results of a series of tests conducted in near-natural conditions, which represent almost real-time reactions between the drug and the host.

As of 2017, approximately 43.0% of ADME toxicology testing areas carried out are based on cell culture tech. Cell culture technology is adopted widely owing to advantages such as near-natural conditions and accurate results obtained at a cellular level.

These assays are conducted for several types of toxic reactions or systems where toxic reactions might take place. Some of the toxicity tests are systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicities that might result in living tissue. Advancements in testing methods are underway and this trend is likely to be picked up by many companies developing drug molecules. This will speed up the drug discovery process and boost the market growth.

 Request a free sample copy or view report summary: ADME Toxicology Testing Market Report

ADME Toxicology Testing Market Report Highlights

• The market is driven by an increasing ratio of late-stage drug failures, resulting in loss of valuable time and investment for drug development. Growth and increasing adoption of OMICS technology is also expected to boost revenue generation in the coming years

• North America is the largest market for ADME toxicology testing owing to the presence of a large number of pharmaceutical companies competing for the commercial launch of novel molecules

• Developing regions of Asia Pacific and Latin America are set to grow considerably as many multinational and local players are striving to enter the market. They are also looking to improve their hold in markets that present innovation and growth opportunities

ADME Toxicology Testing Market Segmentation

Grand View Research has segmented the global ADME toxicology testing market based on technology, application, method, and region:

ADME Toxicology Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Culture Tech

• High Throughput Tech

• Molecular Imaging Tech

• OMICS Technology

ADME Toxicology Testing Method Provider Outlook (Revenue, USD Million, 2018 - 2030)

• Cellular Assay

• Biochemical Assay

• In-Silica

• Ex-vivo

ADME Toxicology Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Systemic Toxicity

• Renal Toxicity

• Hepatotoxicity

• Neurotoxicity

• Other Toxicities

ADME Toxicology Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in ADME Toxicology Testing Market

• Thermo Fisher Scientific, Inc.

• Danaher

• Charles River Laboratories

• Promega Corporation

• Agilent Technologies, Inc.

• Curia Global, Inc.

• Dassault Systèmes

• Catalent, Inc

• Labcorp

• Eurofins Scientific

• Miltenyi Biotec

• IQVIA Inc.